PhD  Ioannis Papassotirio  has published an interesting Article When to determine NGAL (Neutrophil Gelatinase Associated Lipocalin) levels in Plasma and/or in Urine.

As Dr Papassotirio points out, a rise in NGAL levels is also seen in connection with other conditions – apart from AKI.

the key quote from the article is this; Provocatively proposed as “the troponin of the kidney”, several reliable clues have now been gathered that the current assessment of NGAL by commercial methods is anything but specific for renal injury as yet. Undeniably, the introduction of NGAL brought valuable gains for early diagnosis of AKI, but yet this enigmatic protein is far from being considered “the” ideal biomarker.

I agree – or rather I agree in-as-much,  as you have to see a significant rise in NGAL levels in order to determine whether the patient suffers from AKI or not. Hence the proposed cut-off value by BioPort 250 ng/ml which effectively discriminates between AKI-related NAGL and not AKI-related NGAL-levels.

About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂


Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.